Results 41 to 50 of about 14,398,598 (290)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin

open access: yesOncoImmunology, 2023
Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironment.
Daniel Snell   +22 more
doaj   +1 more source

Engaging T cells for cleanup

open access: yesFrontiers in Immunology
T-cell engagers represent a transformative approach to cancer immunotherapy leveraging bispecific and multispecific antibody constructs to redirect T-cell cytotoxicity toward malignant cells. These molecules bridge T cells and tumor cells by simultaneously binding CD3 on T cells and tumor-associated antigens on cancer cells, thereby enabling precise ...
Roman V. Mungalov   +11 more
openaire   +3 more sources

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia [PDF]

open access: yes, 2015
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g ...
Delong Liu   +7 more
core   +1 more source

Protocol for the concept and development of T cells secreting αCD133-αCD3 bispecific T cell engager (αCD133-αCD3 ENG).

open access: yes, 2022
(A) Production of T cells secreting αCD133-αCD3 engager. Peripheral blood mononuclear cells (PBMCs) were isolated and transduced with lentiviruses carrying cDNA encoding αCD133-αCD3-ENG to obtain final products, which are a mixture of untransduced and ...
Thanich Sangsuwannukul (12269800)   +6 more
core   +1 more source

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma

open access: yesOncoImmunology, 2022
B cell lymphoma therapy has been transformed by CD19-targeting cellular therapeutics that induce high clinical response rates and impressive remissions in relapsed and refractory patients.
Lihe Su   +4 more
doaj   +1 more source

CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes. [PDF]

open access: yesMol Ther
Ruck T   +12 more
europepmc   +2 more sources

Evidence‐Informed Multidisciplinary Consensus Guidance for the Psychosocial Care of Adolescents With High‐Risk Cancer: Recommendations From the Italian Association of Pediatric Hematology and Oncology

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adolescents with high‐risk cancer face complex developmental, psychosocial, and ethical challenges that extend beyond disease‐directed treatment. Although international recommendations exist for communication, psychosocial care, pediatric palliative care, survivorship, and shared decision‐making, these have largely evolved within ...
Johanna M. C. Blom   +15 more
wiley   +1 more source

Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani   +7 more
wiley   +1 more source

Infographic – Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

open access: yes, 2022
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine ...
Valentina Gambardella (13027563)   +9 more
core   +1 more source

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells [PDF]

open access: yes, 2022
SIMPLE SUMMARY: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and still orphan hematologic malignancy. No effective immunotherapeutic strategies are presently available for this poor prognosis disease.
Simona Sestito   +50 more
core   +1 more source

Home - About - Disclaimer - Privacy